CVRdatabase
Menu

Danipharm A/S

Public limited companyCVR 12335040KastrupActive

Danipharm A/S is a public limited company, based in Kastrup, active in manufacture of basic pharmaceutical products, founded in 1988. Net profit rose 168% from 2024 to 2025, ending at DKK 13.7m. Measured by gross profit, it ranks no. 5 of 14 companies in the industry in the database. Equity grew to DKK 60.3m in 2025.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profitDKK 37.6m+10.3% vs. 2024
Net profitDKK 13.7m+168.2% vs. 2024
EquityDKK 60.3m+29.5% vs. 2024
Employees24latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • Gross profit rose 10% (2024 → 2025), to DKK 37.6m.
  • Net profit rose 168% (2024 → 2025), to DKK 13.7m.
  • Equity rose 29% (2024 → 2025), to DKK 60.3m.

Employees

  • 1 fewer employees than a year earlier: 24 (08/2026) against 25 (08/2025).

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

DKK 0DKK 10mDKK 20mDKK 30mDKK 40mDKK 50mDKK 60m202020212022202320242025
EquityNet profit
Financial figures for Danipharm A/S
202020212022202320242025Change
Revenue91,597not statednot statednot statednot statednot stated–
Gross profit31,63929,39534,93535,15234,06537,587+10.3%
Operating profit (EBIT)7,4024,5699,2178,0567,02817,062+142.8%
Profit before tax7,3933,77210,4996,9066,55217,583+168.4%
Net profit5,7672,9448,1915,3915,11413,717+168.2%
Total assets68,94273,17878,30787,07695,569112,993+18.2%
Equity26,92429,86936,05941,45046,56460,281+29.5%
Liabilities40,32341,50140,44743,78147,38151,177+8%
Cash and cash equivalents1489950020−88.1%
Average number of employees222526–28280%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

DKK 0DKK 5mDKK 10mDKK 15mDKK 20mDKK 25mDKK 30mDKK 35mDKK 40m202020212022202320242025
Gross profitMedian, the industry (14 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Profit for five years in a row

    Net result has been positive in 2021–2025.

    How is this calculated?

    Net result is positive in the five latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Danipharm A/S
Financial yearPeriodPublishedFigures forDocuments
202501/07/2024 – 30/06/202510/12/2025The companyPDF not statedXBRL
202401/07/2023 – 30/06/202413/12/2024The companyPDFXBRL
202301/07/2022 – 30/06/202321/12/2023The companyPDFXBRL
202201/07/2021 – 30/06/202205/12/2022The companyPDFXBRL
202101/07/2020 – 30/06/202107/12/2021The companyPDFXBRL
202001/07/2019 – 30/06/202007/11/2020The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
05101520253009/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/2608/26
Employees

Position in the industry

14 companies in the database

Comparison with the other companies in manufacture of basic pharmaceutical products based on the latest financial year.

Gross profitDKK 37.6mNo. 5 of 14
Better than 69% of the companies in the industry
EquityDKK 60.3mNo. 5 of 14
Better than 69% of the companies in the industry
Number of employees24No. 7 of 14
Better than 54% of the companies in the industry

Industry median: gross profit DKK 13.9m, net profit DKK 80,789, equity DKK 10.1m, 19 employees.

DKK 100kDKK 749kDKK 5.6mDKK 42mDKK 161mHere
Distribution of gross profit for 14 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 20–49 employees9,922 companies in the comparison
No. 833of 9,892
Better than 92%
No. 595of 9,922
Better than 94%
Companies that are at least 30 years old10,276 companies in the comparison
No. 1,839of 10,152
Better than 82%
No. 1,787of 10,275
Better than 83%
All companies of type A/S18,025 companies in the comparison
No. 3,705of 17,786
Better than 79%
No. 3,188of 18,024
Better than 82%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of basic pharmaceutical products
Gross profit
  1. Danipharm A/SDKK 37.6m
  2. Xellia Pharmaceuticals ApSDKK 314.9m
  3. Glycom Manufacturing A/SDKK 226.3m
Net profit
  1. Danipharm A/SDKK 13.7m
  2. Xellia Pharmaceuticals ApSDKK 213.7m
  3. Glycom Manufacturing A/SDKK 69.2m
Equity
  1. Danipharm A/SDKK 60.3m
  2. Xellia Pharmaceuticals ApSDKK 404.6m
  3. Glycom Manufacturing A/SDKK 577.7m
Employees
  1. Danipharm A/S24
  2. Xellia Pharmaceuticals ApS458
  3. Glycom Manufacturing A/S116

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • H&P Rørvig Holding A/S100%
Danipharm A/S

Management

4 active registrations

Executive management

Executive management at Danipharm A/S
NameRoleAppointed
Peter RørvigDirector31/05/2006

Board of directors

Board of directors at Danipharm A/S
NameRoleAppointed
Helle RørvigBoard member30/11/2005
Niels Ulrik HeineChair of the board31/05/2006
Peter RørvigBoard member31/05/2006
Founders
VX 10.312 ApS
Former management (6)
Former management at Danipharm A/S
NameRoleAppointedResigned
Per Emil Hasselbalch StakemannDirector01/08/198822/12/1988
Niels Otto ThiesenDirector01/08/198831/05/2006
Erik Vilhelm BalslevBoard member11/11/199618/02/1998
Erik Vilhelm BalslevDirector11/11/199611/11/1996
Niels Otto ThiesenBoard member11/11/199608/09/2006
Svend BlankholmBoard member23/11/200413/02/2020

Signing rule: Selskabet tegnes af en direktør eller af et bestyrelsesmedlem.

Address and production units

1 active production units

Englandsvej 350
2770 Kastrup

Tårnby Municipality · Postcode 2770

Other companies at the address (2)

Production units
Production unitAddressEmployeesP number
DANIPHARM A/SSkalhuse 3, Gelstrup, 9240 Nibe241002919144

Purpose

Selskabets formål er at drive handel, produktion og forskning

The purpose is quoted from the register in Danish.

Changes year by year

30 registered events
20251 changeaccounts 1
  • Annual report for 2025 published
20241 changeaccounts 1
  • Annual report for 2024 published
20231 changeaccounts 1
  • Annual report for 2023 published
20221 changeaccounts 1
  • Annual report for 2022 published
20213 changesaccounts 1 · address 2
  • Annual report for 2021 published
  • Moved to Englandsvej 350-356, 2770 Kastrup
  • Moved to Englandsvej 350-356, 2770 Kastrup
20202 changesaccounts 1 · management 1
  • Annual report for 2020 published
  • Svend Blankholm stepped down as board member
20171 changeaddress 1
  • Moved to Englandsvej 350-356, 2770 Kastrup
20091 changeownership 1
  • H&P Rørvig Holding A/S registered as owner (100%)
20065 changesmanagement 5
  • Niels Otto Thiesen stepped down as board member
  • Peter Rørvig appointed director
  • Peter Rørvig appointed board member
  • Niels Ulrik Heine appointed chair of the board
  • Niels Otto Thiesen stepped down as director
20051 changemanagement 1
  • Helle Rørvig appointed board member
20041 changemanagement 1
  • Svend Blankholm appointed board member
19981 changemanagement 1
  • Erik Vilhelm Balslev stepped down as board member
19965 changescapital 1 · management 4
  • Share capital changed from 250,000 DKK to 500,000 DKK
  • Niels Otto Thiesen appointed board member
  • Erik Vilhelm Balslev appointed director
  • Erik Vilhelm Balslev stepped down as director
  • Erik Vilhelm Balslev appointed board member
19886 changesname 1 · capital 1 · management 3 · founded 1
  • Name changed from ApS KBUS 8 NR.3500 to DANIPHARM A/S
  • Share capital changed from 80,000 DKK to 250,000 DKK
  • Per Emil Hasselbalch Stakemann stepped down as director
  • Registered as ApS KBUS 8 NR.3500
  • Per Emil Hasselbalch Stakemann appointed director
  • Niels Otto Thiesen appointed director

Related companies

Same industry in Tårnby

See all →

Same people in management

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.

View in CVRReport a correction